AMIFLEX BY VÉTO-PHARMA Trademark
Serial Number: 79275187 • Registration: 6208000
AMIFLEX BY VÉTO-PHARMA is a trademark filed by
VETO-PHARMA
on October 29, 2019. The trademark is classified under Class 5 (Pharmaceuticals).
The application is currently registered and active.
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
Mary L Grieco OLSHAN FROME WOLOSKY
1325 Avenue of the Americas
New York, NY 10019
UNITED STATES
Trademark Details
Filing Date
October 29, 2019
Registration Date
December 1, 2020
Published for Opposition
September 15, 2020
Goods & Services
Anti-varroa-mite treatment for bees in the nature of acaricides; bee acaricides
Filing History
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Dec 1, 2025 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Nov 17, 2023 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 21, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 2, 2021 FICS
FINAL DISPOSITION PROCESSED
Mar 2, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 1, 2021 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Feb 27, 2021 NREP
REGISTERED-PRINCIPAL REGISTER
Dec 1, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 15, 2020 NPUB
PUBLISHED FOR OPPOSITION
Sep 15, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 7, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 1, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 31, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 31, 2020 TROA
REFUSAL PROCESSED BY IB
Mar 21, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 4, 2020 RFCS
REFUSAL PROCESSED BY MPU
Mar 4, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 7, 2020 RFCR
NON-FINAL ACTION WRITTEN
Feb 6, 2020 CNRT
ASSIGNED TO EXAMINER
Feb 3, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 10, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 6, 2020 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Dec 31, 2019 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 26, 2019 REPR
